Training and Resources

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

KEYTRUDA® (pembrolizumab) in cervical cancer

KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a combined positive score (CPS) ≥1.

PD-L1 testing and CPS interpretation in cervical cancer

Please refer to Summary of Product Characteristics for full list of AEs and management.

More information about KEYTRUDA® (pembrolizumab) in cervical cancer

KEYTRUDA® (pembrolizumab) in endometrial cancer

KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation.

More information about KEYTRUDA® (pembrolizumab) in endometrial cancer

KEYTRUDA® in combination with chemotherapy

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website